CN108095084A - 一种大叶藻海参保健食品及其制备方法 - Google Patents
一种大叶藻海参保健食品及其制备方法 Download PDFInfo
- Publication number
- CN108095084A CN108095084A CN201711421483.2A CN201711421483A CN108095084A CN 108095084 A CN108095084 A CN 108095084A CN 201711421483 A CN201711421483 A CN 201711421483A CN 108095084 A CN108095084 A CN 108095084A
- Authority
- CN
- China
- Prior art keywords
- lys
- gly
- zostera marina
- sea cucumber
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001148683 Zostera marina Species 0.000 title claims abstract description 81
- 235000013402 health food Nutrition 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 12
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 80
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims abstract description 80
- 241000251511 Holothuroidea Species 0.000 claims abstract description 70
- 239000000463 material Substances 0.000 claims abstract description 32
- 239000000853 adhesive Substances 0.000 claims abstract description 9
- 230000001070 adhesive effect Effects 0.000 claims abstract description 9
- 239000000945 filler Substances 0.000 claims abstract description 9
- 239000007884 disintegrant Substances 0.000 claims abstract description 8
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- 239000002702 enteric coating Substances 0.000 claims abstract description 7
- 238000009505 enteric coating Methods 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- 229920002472 Starch Polymers 0.000 claims description 19
- 239000008107 starch Substances 0.000 claims description 19
- 235000019698 starch Nutrition 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002002 slurry Substances 0.000 claims description 11
- 229920001661 Chitosan Polymers 0.000 claims description 10
- 235000013339 cereals Nutrition 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 230000009849 deactivation Effects 0.000 claims description 6
- 239000003651 drinking water Substances 0.000 claims description 6
- 235000020188 drinking water Nutrition 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 235000013372 meat Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000001976 enzyme digestion Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 238000010612 desalination reaction Methods 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims 7
- -1 phthalate ester Chemical class 0.000 claims 1
- 229940080313 sodium starch Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000003712 anti-aging effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 230000036772 blood pressure Effects 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical class OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000965254 Apostichopus japonicus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000022972 amelogenesis Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000013860 dentinogenesis Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000008496 endemic goiter Diseases 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及保健食品领域。一种大叶藻海参保健食品,一种大叶藻海参保健食品,其特征在于,由海参肽粉和大叶藻肽粉和辅料组成,辅料选自肠溶衣、崩解剂、粘合剂、填充剂、润滑剂中的部分或全部,辅料总重量不超过海参大叶藻粉重量的5倍。本发明将营养全面的海参和大叶藻很好的进行了融合,实现了海洋植物蛋白和海洋动物蛋白的最优组合。本申请通过酶解制得肽粉,使得海参和大叶藻中各种有效成分能充分被人体吸收。另外本申请通过海参多肽和大叶藻多肽的协同增效作用获得一种全新的功能性食品,具有增强人体免疫力、改善睡眠、延缓衰老、降血压、降血脂、壮阳、抗癌、抗辐射等作用。
Description
技术领域
本发明涉及保健品领域,具体涉及一种大叶藻及海参类保健品。
背景技术
片剂是一味或多味药物加工或提取后与辅料混合压制而成的片状制剂。主要供内服。片剂用量准确,体积小,便于服用、贮存和运输。味苦或有臭味的药物经压片后可包糖衣。需要在肠道内起作用或遇胃酸易被破坏的药物可包肠溶衣,以便在肠道中崩解发挥药效。由于人体内消化系统对蛋白质和肽的吸收有着层层阻碍,生物活性肽能否在人体内完整地被吸收并传送至目标位置,产生生理效应,是现有肽类药物和保健品的有待解决的关键性问题。为了克服大多数肽口服后的生物学效应低下的现象,现有方法的基本策略是:保护肽免遭肠道酶系的降解;增强肽在小肠黏膜的透过性。主要的方法有:(1)采用定点释放技术;(2)使用蛋白酶抑制剂和吸收增强剂;(3)延长肽在吸收位点的滞留时间。
海参是世界上少有的高蛋白、低脂肪、低糖、无胆固醇的天然保健食品。现代科学研究证明,海参含有50多种对人体生理活动有益的营养成分和多种微量元素,尤其是海参体内特异性的生理活性物质对人体具有显著的保健和辅助医疗作用。海参含有的酸性粘多糖和软骨素可明显降低心脏组织中脂褐素和皮肤脯氨酸的数量,起到延缓衰老的作用。海参能调节人体水份平衡,适宜于孕期腿脚浮肿的女士。海参能消除疲劳,提高人体免疫力,增强人体抵抗疾病的能力,因此非常适合经常处于疲劳状态的中年女士与男士,易感冒、体质弱的老年人和儿童等亚健康人群。海参体内的精氨酸含量很高,号称精氨酸大富翁。精氨酸是构成男性精细胞的主要成份,具有改善脑、性腺神经功能传导作用,减缓性腺衰老,提高勃起能力。海参中的牛磺酸、赖氨酸等在植物性食品中几乎没有。海参特有的活性物质海参素,对多种真菌有显著的抑制作用,刺参素A和B可用于治疗真菌和白癣菌感染,具有显著的抗炎、成骨作用,尤其对肝炎患者、结核病、糖尿病、心血管病有显著的治疗作用。海参皂苷是一种抗毒剂,对人体安全无毒,但能抑制肿瘤细胞的生长与转移,有效防癌、抗癌,临床上已广泛应用于肝癌、肺癌、胃癌、鼻咽癌、骨癌、淋巴癌、卵巢癌、子宫癌、乳腺癌、脑癌白血病及手术后患者的治疗。海参中丰富的钙、磷、锰、铜、锗、硅等元素对预防婴儿佝偻病,成人的骨质疏松症以及对骨骼异常、畸形,牙质及釉质发育不良都有特殊作用。
大叶藻,多年生沉水草本。有根状匍匐茎,节上生须根;茎细,有疏分枝。含有多种有机物和碘、钾、钙、铁等元素,还含蛋白质、脂肪酸、糖类、多种维生素和尼克酸等。可防治地方性甲状腺肿,显著降低胆固醇。对高血压、动脉硬化及脂肪过多症有一定的预防和辅助治疗作用。
随着生活节奏日益加快,且生活无规律,竞争的压力越来越大,许多人的免疫力较差,身体呈现亚健康状况;并且中国人口老龄化的加剧使得越来越多的人注重延年益寿,美容养颜。最有效的调节人体机能的办法就是补充全面均衡的营养,来达到最佳的身体状态。可以通过一种营养全面均衡且容易被人体吸的保健食品来实现。
现有保健品种类繁多,但多存在营养素单一、人体吸收差、安全性一般等等缺陷。
发明内容
本发明的目的解决上述不足问题,提供一种大叶藻海参片保健食品,实现了海洋动物蛋白和海洋植物蛋白,海洋动物多糖和海洋植物多糖的最佳组合,更加易于人体吸收,调节机体平衡,达到增强免疫力、美容养颜、延缓衰老的目的。
本发明为解决上述问题所采用的技术方案是:一种大叶藻海参保健食品,其特征在于,由海参肽粉和大叶藻肽粉和辅料组成,辅料选自肠溶衣、崩解剂、粘合剂、填充剂、润滑剂中的部分或全部,辅料总重量不超过海参大叶藻粉重量的5倍。
所述填充剂可以为:乳糖、磷酸氢钙或糊精等;崩解剂可以为:干淀粉和羧甲基淀粉钠等;粘合剂可以为:淀粉浆等;润滑剂可以为硬脂酸镁;肠溶衣可以为羟丙基纤维素酞酸酯等。
所述的一种大叶藻海参保健食品,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 50份
大叶藻肽粉 50份
淀粉浆 10份
硬脂酸镁 1份
壳聚糖 1份。
所述的一种大叶藻海参保健食品,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 60份
大叶藻肽粉 40份
糊精 100份
羧甲基淀粉钠 10份
淀粉浆 20份
硬脂酸镁 2份
壳聚糖 2份。
所述的一种大叶藻海参保健食品,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 400份
大叶藻肽粉 300份
乳糖 200份
磷酸氢钙 100份
羧甲基淀粉钠 100份
淀粉浆 200份
硬脂酸镁 10份
壳聚糖 10份。
所述的一种大叶藻海参保健食品,所述海参肽粉是由是由北纬39度平岛基地的海参制得。
所述的一种大叶藻海参保健食品,所述其大叶藻肽粉是由北纬39度平岛基地提供的大叶藻制得。
所述的一种大叶藻海参保健食品的制备方法,包括如下步骤:
1)海参肽粉的加工:以拉缸盐海参为原料,经清洗去砸除盐;绞肉机绞碎后磨浆,磨浆细度控制在5μm 以下;将磨浆后的物料打入酶解缸内,加饮用水调整浓度至8%~10%,加入复合蛋白酶制剂;酶解4小时待反应完成后迅速升温至85~90℃,保持15~30min,在灭酶的同时进行杀菌;过滤;喷雾干燥,干燥后的海参肽粉在洁净室内冷却装袋备用;
2)大叶藻肽粉的加工:以新鲜的大叶藻为原料,经清洗去砸;绞肉机绞碎后磨浆,磨浆细度控制在5μm 以下;将磨浆后的物料打入酶解缸内,加饮用水调整浓度至8%~10%,加入复合蛋白酶制剂;酶解反应完成后迅速升温至85~90℃,保持15~30min,在灭酶的同时进行杀菌;过滤;喷雾干燥,干燥后的大叶藻肽粉在洁净室内冷却装袋备用;
3)大叶藻海参片剂的生产工艺:按照处方量称取海参肽粉、大叶藻肽粉,加入崩解剂、填充剂、粘合剂混合均匀,制成湿粒,40-60℃低温干燥后得干粒,整粒后再加入润滑剂混合,压片,水分控制在≦5%,再用高分子薄膜衣包衣,增重0-20%,制得糖衣片剂。
本发明保健食品实现了海参和大叶藻的完美组合,实现了海洋动物蛋白和海洋植物蛋白,海洋动物多糖和海洋植物多糖的最佳组合,使动物营养素与植物营养素最优组合,使营养成分不再单一,作用更强化。通过片剂肠溶衣包裹达到定点释放和延长吸收时间,通过添加吸收增强剂壳聚糖促进营养吸收。本发明是一种配比合理,营养全面均衡,易于吸收,安全可靠的动植物营养素双补的保健品。
另外本发明大叶藻海参片剂的制备方法,工艺简单,能完全保留海参和大叶藻的活性成分,在体内更容易被吸收,并能减少海参其它剂型(胶囊、口服液)服用时易产生的海腥味,更易服用,容易保存。更加易于人体吸收,调节机体平衡,达到增强免疫力、美容养颜、延缓衰老的目的。
附图说明
图1 是本发明大叶藻海参保健食品的生产工艺流程图。
具体实施方式
下面通过具体实施例对本发明作进一步详细说明,但本发明并不局限于实施例。
本发明大叶藻海参保健食品主要由海参肽粉、大叶藻肽粉及辅料组成。其特征在于辅料由肠溶衣、崩解剂、粘合剂、填充剂、润滑剂中部分或全部,其总重量不超过海参大叶藻粉重量的5倍,制成片剂。
实施例1:
大叶藻海参保健食品,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 50份
大叶藻肽粉 50份
淀粉浆 10份
硬脂酸镁 1份
壳聚糖 1份。
实施例2:
大叶藻海参保健食品,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 60份
大叶藻肽粉 40份
糊精 100份
羧甲基淀粉钠 10份
淀粉浆 20份
硬脂酸镁 2份
壳聚糖 2份。
实施例3:
大叶藻海参保健食品,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 400份
大叶藻肽粉 300份
乳糖 200份
磷酸氢钙 100份
羧甲基淀粉钠 100份
淀粉浆 200份
硬脂酸镁 10份
壳聚糖 10份。
以上三个实施例产品的制备方法:包括海参肽粉的加工、大叶藻肽粉的加工、制粒、干燥、压片、包衣等步骤。
海参肽粉的加工:以拉缸盐海参为原料,经清洗去砸除盐;绞肉机绞碎后磨浆,磨浆细度控制在5μm 以下;将磨浆后的物料打入酶解缸内,加饮用水调整浓度至10%,加入酶制剂;酶解反应完成后迅速升温至85℃,保持25min,在灭酶的同时进行杀菌;过滤;喷雾干燥,干燥后的海参肽粉在洁净室内冷却装袋备用。
大叶藻粉的加工:以新鲜的大叶藻为原料,经清洗去砸;绞肉机绞碎后磨浆,磨浆细度控制在5μm 以下;将磨浆后的物料打入酶解缸内,加饮用水调整浓度至10%,加入酶制剂;酶解反应完成后迅速升温至90℃,保持30min,在灭酶的同时进行杀菌;过滤;喷雾干燥,干燥后的大叶藻肽粉在洁净室内冷却装袋备用。
大叶藻海参片剂的生产工艺:按照处方量称取海参肽粉、大叶藻肽粉,加入崩解剂、填充剂、粘合剂混合均匀,制成湿粒,低温干燥(50℃)后得干粒,整粒后再加入润滑剂混合,压片,水分控制在≦5%。再用高分子薄膜衣包衣(MC、HPMC、HEC和HPC等),增重10%。
实施例4:海参肽粉、大叶藻肽粉及辅料混合制成湿粒后,低温干燥温度为40℃,其余同实施例4。
实施例5:海参肽粉、大叶藻肽粉及辅料混合制成湿粒后,低温干燥温度为45℃,其余同实施例4。
实施例6:海参肽粉、大叶藻肽粉及辅料混合制成湿粒后,低温干燥温度为50℃,其余同实施例4。
实施例7:海参肽粉、大叶藻肽粉及辅料混合制成湿粒后,低温干燥温度为55℃,其余同实施例4。
实施例8:海参肽粉、大叶藻肽粉及辅料混合制成湿粒后,低温干燥温度为60℃,其余同实施例4。
Claims (8)
1.一种大叶藻海参保健食品,其特征在于,由海参肽粉和大叶藻肽粉和辅料组成,辅料选自肠溶衣、崩解剂、粘合剂、填充剂、润滑剂中的部分或全部,辅料总重量不超过海参大叶藻粉重量的5倍。
2.根据权利要求1所述的一种大叶藻海参保健食品,其特征在于,所述海参肽粉和大叶藻肽粉的重量比为1-3:1-2;填充剂选自乳糖、磷酸氢钙和糊精;崩解剂选自干淀粉和羧甲基淀粉钠;粘合剂为淀粉浆;润滑剂为硬脂酸镁;肠溶衣为羟丙基纤维素酞酸酯。
3.根据权利要求书1所述的一种大叶藻海参保健食品,其特征在于,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 50份
大叶藻肽粉 50份
淀粉浆 10份
硬脂酸镁 1份
壳聚糖 1份。
4.根据权利要求书1所述的一种大叶藻海参保健食品,其特征在于,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 60份
大叶藻肽粉 40份
糊精 100份
羧甲基淀粉钠 10份
淀粉浆 20份
硬脂酸镁 2份
壳聚糖 2份。
5.根据权利要求书1所述的一种大叶藻海参保健食品,其特征在于,海参肽粉、大叶藻肽粉及辅料组成及重量配比如下:
海参肽粉 400份
大叶藻肽粉 300份
乳糖 200份
磷酸氢钙 100份
羧甲基淀粉钠 100份
淀粉浆 200份
硬脂酸镁 10份
壳聚糖 10份。
6.根据权利要求书1-5任一所述的一种大叶藻海参保健食品,其特征在于,所述海参肽粉是由是由北纬39度平岛基地的海参制得。
7.根据权利要求书1-5任一所述的一种大叶藻海参保健食品,其特征在于,所述其大叶藻肽粉是由北纬39度平岛基地提供的大叶藻制得。
8.根据权利要求1-5任一所述的一种大叶藻海参保健食品的制备方法,其特征在于,包括如下步骤:
1)海参肽粉的加工:以拉缸盐海参为原料,经清洗去砸除盐;绞肉机绞碎后磨浆,磨浆细度控制在5μm 以下;将磨浆后的物料打入酶解缸内,加饮用水调整浓度至8%~10%,加入复合蛋白酶制剂;酶解4小时待反应完成后迅速升温至85~90℃,保持15~30min,在灭酶的同时进行杀菌;过滤;喷雾干燥,干燥后的海参肽粉在洁净室内冷却装袋备用;
2)大叶藻肽粉的加工:以新鲜的大叶藻为原料,经清洗去砸;绞肉机绞碎后磨浆,磨浆细度控制在5μm 以下;将磨浆后的物料打入酶解缸内,加饮用水调整浓度至8%~10%,加入复合蛋白酶制剂;酶解反应完成后迅速升温至85~90℃,保持15~30min,在灭酶的同时进行杀菌;过滤;喷雾干燥,干燥后的大叶藻肽粉在洁净室内冷却装袋备用;
3)大叶藻海参片剂的生产工艺:按照处方量称取海参肽粉、大叶藻肽粉,加入崩解剂、填充剂、粘合剂混合均匀,制成湿粒,40-60℃低温干燥后得干粒,整粒后再加入润滑剂混合,压片,水分控制在≦5%,再用高分子薄膜衣包衣,增重0-20%,制得糖衣片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711421483.2A CN108095084A (zh) | 2017-12-25 | 2017-12-25 | 一种大叶藻海参保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711421483.2A CN108095084A (zh) | 2017-12-25 | 2017-12-25 | 一种大叶藻海参保健食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108095084A true CN108095084A (zh) | 2018-06-01 |
Family
ID=62212814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711421483.2A Pending CN108095084A (zh) | 2017-12-25 | 2017-12-25 | 一种大叶藻海参保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108095084A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110192625A (zh) * | 2019-07-05 | 2019-09-03 | 福建冠丰生物科技有限公司 | 一种浓缩海参油软胶囊的制备方法 |
-
2017
- 2017-12-25 CN CN201711421483.2A patent/CN108095084A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110192625A (zh) * | 2019-07-05 | 2019-09-03 | 福建冠丰生物科技有限公司 | 一种浓缩海参油软胶囊的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI516280B (zh) | 紅藜萃取物用於製備促進膠原蛋白生成及抗皮膚老化之組合物之用途 | |
CN104855845A (zh) | 一种纳豆营养健康食品 | |
CN103416625A (zh) | 一种大麦型仔猪饲料及其制备方法 | |
CN113632851A (zh) | 一种多功能儿童生长奶粉及其制备方法 | |
CN107213451A (zh) | 改善人体微循环障碍的益生菌发酵中药制剂及其制备方法 | |
CN105942297A (zh) | 一种海参粉及制备方法 | |
CN104397576A (zh) | 一种超微黑木耳粉营养强化粥及其制备方法 | |
CN107319242A (zh) | 左旋肉碱减肥泡腾片及其制备方法 | |
CN101455378A (zh) | 一种含有苦荞的保健品及其制备方法 | |
CN104472612A (zh) | 能够调理肠胃的面包所用天然酵母面包预拌粉 | |
CN111184214A (zh) | 酵素胶原蛋白杂粮果蔬即食代餐粥及其制作方法 | |
CN102657304A (zh) | 一种具有促进消化和缓解体力疲劳双功能的保健食品 | |
CN102659917A (zh) | 一种从松花粉中分离制备粗蛋白及酶解肽类的方法 | |
CN102018158A (zh) | 一种芦荟果酱 | |
CN108095084A (zh) | 一种大叶藻海参保健食品及其制备方法 | |
CN101675800B (zh) | 一种妇女产后滋补膏及制备方法 | |
CN104382002A (zh) | 一种缓解疲劳的玛咖片 | |
CN108813453A (zh) | 一种防治帕金森病的食用组合物 | |
CN107897621A (zh) | 一种鲍鱼泡腾片生产方法 | |
CN102511882A (zh) | 一种有助于改善生长发育的红枣浓浆 | |
KR101119272B1 (ko) | 농작물을 유효성분으로 함유하는 약학적 조성물 | |
CN113349380A (zh) | 一种含牡蛎复合肽肾功能改善剂及其制备方法 | |
KR100734944B1 (ko) | 젖산칼슘 및 미강을 주재로 한 기능성 건강식품 조성물 | |
CN108719981A (zh) | 一种微生物酵素钙泡腾片的制备方法 | |
CN108524850A (zh) | 一种用于增强免疫、防治心脑血管疾病的酒制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180601 |
|
WD01 | Invention patent application deemed withdrawn after publication |